TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/06/2026
Voltar para busca
Dado oficial do USPTO
PAIGE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
57
Atualização mais recente
19/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42, 44
Data de depósito
20/02/2019
Data de registro
24/11/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/03/2026
Última transação
19/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
702
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
21/02/2019
Primeiro uso no comércio
21/02/2019
Código do desenho
4
Tipo de titular
03
Localização do titular
New York, NY, US
Examinador
MORRIS, KRISTINA KLOIBER
Localização atual
Historical data usage
Titulares e representantes
Titulares
PAIGE.AI, Inc.
Representantes
Mark Leonardo NUTTER, MCCLENNEN & FISH, LLP
Classificação técnica
Classes Nice
Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Software as a service (SaaS) services featuring software for artificial intelligencemachine learningdeep learningstatistical learningdata miningcontextual prediction; software as a service (SaaS) services featuring software for use in disease pathologysoftware that reads digital slides and provides diagnoses; software as a service (SaaS) services featuring software for use in diagnosis of diseasesstatesconditions; software as a service (SaaS) services featuring software for use in evaluation of prognosis relating to diseasesstatesconditions; software as a service (SaaS) services featuring software for use in monitoring of diseasesstatesconditions; software as a service (SaaS) services featuring software for use to detect or identify predispositions to diseasesstatesconditions; software as a service (SaaS) services featuring software to detect the recurrence of diseasesstatesconditions; software as a service (SaaS) services featuring software to detectmonitorevaluate patients' responses to treatment of diseasesstatesconditions; software as a service (SaaS) services featuring software for use in clinical management of diseasesstatesconditions; software as a service (SaaS) services featuring software for use in the selection of treatment of diseasesstatesconditions; software as a service (SaaS) services featuring software for use in prevention of diseasesstatesconditions; software as a service (SaaS) services featuring software for use in palliation or treatment of diseasesstatesconditions; software as a service (SaaS) services featuring software for use in research or development in the field of life sciences; software as a service (SaaS) services featuring software for use in research or development in the field of medicine; software as a service (SaaS) services featuring software for use in research or development in the field of healthcare; software as a service (SaaS) services featuring software for use in research or development in the field of cancer; software as a service (SaaS) services featuring software for use in research or development in the field of oncology; software as a service (SaaS) services featuring software for use in research or development in the field of pathology; design and development of AI-powered computer software that analyzes clinical pathology slides and diagnoses diseases; medical research; scientific research and development services in the field of pathology; research and development services in the field of medicine; research and development services in the field of cancer; research and development services in the field of healthcare; research and development services in the field of life sciences; research and development services in the field of oncology; medical and scientific research services in the field of pathology; medical and scientific research services in the field of cancer; medical and scientific research services in the field of healthcare; medical and scientific research services in the field of life sciences; medical and scientific research services in the field of oncology; research and development of technology in the field of pathology; research and development of technology in the field of medicine; research and development of technology in the field of cancer; research and development of technology in the field of healthcare; research and development of technology in the field of life sciences; research and development of technology in the field of oncology; providing medical research and scientific research information via the internet; electronic scanning of clinical pathology slides; software as a service services (SaaS) featuring software for use in the analysis of clinical pathology slides; medical and scientific testing services for research purposes
Classe 44
Medical services; cancer therapy services; medical testingthe review and analysis of patients' clinical slides to identify additional recommended medical testing; medical testing for the diagnosis of diseasesstatesconditions; medical testing for evaluation of prognosis relating to diseasesstatesconditions; medical testing for the monitoring of diseasesstatesconditions; medical testing to detect or identify predispositions to diseasesstatesconditions; medical testing to detect or determine the recurrence of diseasesstatesconditions; medical testing to detectmonitorevaluate responses to treatment of diseasesstatesconditions; medical testing to evaluate clinical management of diseasesstatesconditions; medical testing for selection of treatment for diseasesstatesconditions; medical testing to evaluate or facilitate prevention of diseasesstatesconditions; medical testing to selectfacilitatemonitorevaluate palliation or treatment of diseasesstates or conditions; medical testing in the field of cancer; medical testing in the field of oncology; medical diagnostic testingmonitoringreporting services; medical analysis or advisory services in the field of cancer; medical analysis or advisory services in the field of oncology; medical analysis or advisory services for medical treatment; medical analysis or advisory services for the diagnosis of diseasesstatesconditions; medical analysis or advisory services for the evaluation of prognosis relating to diseasesstatesconditions; medical analysis or advisory services relating to monitoring diseasesstatesconditions; medical analysis or advisory services relating to the detection or identification of predispositions to diseasesstatesconditions; medical analysis or advisory services relating to the detection or determination of the recurrence of diseasesstatesconditions; medical analysis or advisory services relating to the detectionmonitoringevaluation of responses to treatment of diseasesstatesconditions; medical analysis or advisory services relating to the clinical management of diseasesstatesconditions; medical analysis or advisory services relating to the selection of treatment for diseasesstatesconditions; medical analysis or advisory services relating to the prevention of diseasesstatesconditions; medical analysis or advisory services relating to the palliation or treatment of diseasesstates or conditions; qualitative image analysis in the field of digital pathology for medical purposes; quantitative image analysis in the field of digital pathology for medical purposes; providing non-research related medical information via the internet; medical analysis services for the diagnosis of cancer by reviewing pathological samples on slides
Publicações
Histórico de despachos e eventos da marca no USPTO.
57 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/06/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/06/2026
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
04/03/2026
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
04/03/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/03/2026
E815
TEAS SECTION 8 & 15 RECEIVED
01/12/2025
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
24/11/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
29/01/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/01/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
29/01/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
29/01/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
29/01/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
24/11/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
22/10/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
21/10/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/10/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/10/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
13/10/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/10/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/10/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/10/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
13/10/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/10/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/09/2020
GNRT
NON-FINAL ACTION E-MAILED
11/09/2020
CNRT
SU - NON-FINAL ACTION - WRITTEN
11/09/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
13/08/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/08/2020
IUAF
USE AMENDMENT FILED
31/07/2020
EISU
TEAS STATEMENT OF USE RECEIVED
31/07/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/07/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/07/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/07/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/07/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/07/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
24/04/2020
EX1G
SOU EXTENSION 1 GRANTED
22/04/2020
EXT1
SOU EXTENSION 1 FILED
22/04/2020
EEXT
SOU TEAS EXTENSION RECEIVED
22/04/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
22/10/2019
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
11/09/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/08/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/08/2019
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
31/07/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/07/2019
PUBO
PUBLISHED FOR OPPOSITION
02/07/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/06/2019
ALIE
ASSIGNED TO LIE
29/05/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/05/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
15/05/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
15/05/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
15/05/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
15/05/2019
DOCK
ASSIGNED TO EXAMINER
01/05/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/03/2019
NWAP
NEW APPLICATION ENTERED
23/02/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PAIGE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.